Clinical Trial Update: A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial evaluating whether combining fianlimab with cemiplimab can prevent or delay melanoma recurrence after surgical removal, compare…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• Fianlimab (fianlimab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING